Phil F. Cheng

5.2k total citations
96 papers, 2.9k citations indexed

About

Phil F. Cheng is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Phil F. Cheng has authored 96 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Molecular Biology, 49 papers in Oncology and 21 papers in Immunology. Recurrent topics in Phil F. Cheng's work include Melanoma and MAPK Pathways (38 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Cutaneous Melanoma Detection and Management (18 papers). Phil F. Cheng is often cited by papers focused on Melanoma and MAPK Pathways (38 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Cutaneous Melanoma Detection and Management (18 papers). Phil F. Cheng collaborates with scholars based in Switzerland, United States and Germany. Phil F. Cheng's co-authors include Mitchell P. Levesque, Reinhard Dummer, Lukas Sommer, Daniel Widmer, Ossia M. Eichhoff, Daniel Zingg, Marieke I.G. Raaijmakers, Raffaella Santoro, Holger Moch and Keith S. Hoek and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Phil F. Cheng

93 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Phil F. Cheng Switzerland	29	1.6k	1.3k	827	433	281	96	2.9k
Michael Hölzel Germany	33	2.2k 1.4×	1.7k 1.3×	1.3k 1.6×	588 1.4×	443 1.6×	96	4.3k
Antonella Bacchiocchi United States	18	1.1k 0.7×	1.3k 1.0×	627 0.8×	312 0.7×	266 0.9×	32	2.4k
Lyn M. Duncan United States	22	1.7k 1.1×	1.8k 1.4×	685 0.8×	686 1.6×	225 0.8×	41	3.3k
Jean‐François Baurain Belgium	25	1.1k 0.7×	1.6k 1.3×	1.4k 1.7×	328 0.8×	441 1.6×	103	3.4k
Jan Jacob Schuringa Netherlands	39	2.1k 1.3×	884 0.7×	918 1.1×	570 1.3×	165 0.6×	147	4.1k
Eiji Sugihara Japan	26	1.2k 0.8×	810 0.6×	411 0.5×	546 1.3×	246 0.9×	67	2.3k
Svetlana Sadekova United States	16	1.5k 1.0×	1.1k 0.9×	1.1k 1.3×	648 1.5×	205 0.7×	23	3.1k
Burkhard Helmke Germany	28	1.3k 0.8×	897 0.7×	418 0.5×	484 1.1×	291 1.0×	78	2.9k
Ievgenia Pastushenko Belgium	10	1.6k 1.1×	1.2k 0.9×	271 0.3×	973 2.2×	349 1.2×	16	2.7k
John Sarantopoulos United States	28	1.6k 1.0×	1.3k 1.0×	443 0.5×	382 0.9×	528 1.9×	143	3.2k

Countries citing papers authored by Phil F. Cheng

Since Specialization

Citations

This map shows the geographic impact of Phil F. Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phil F. Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phil F. Cheng more than expected).

Fields of papers citing papers by Phil F. Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phil F. Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phil F. Cheng. The network helps show where Phil F. Cheng may publish in the future.

Co-authorship network of co-authors of Phil F. Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Phil F. Cheng. A scholar is included among the top collaborators of Phil F. Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phil F. Cheng. Phil F. Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheng, Phil F., et al.. (2025). Uncovering the Distinct Role of Phleum p 4 in Grass Pollen Allergy: Sensitization Patterns in 1963 Swiss Patients. International Journal of Molecular Sciences. 26(12). 5616–5616. 1 indexed citations

Rütsche, Dominic, Monica Nanni, Phil F. Cheng, et al.. (2025). Human Dermal Microvascular Arterial and Venous Blood Endothelial Cells and Their Use in Bioengineered Dermo‐Epidermal Skin Substitutes. Small Methods. 9(8). e2401588–e2401588. 1 indexed citations

Dimitriou, Florentia, Phil F. Cheng, Annalisa Saltari, et al.. (2024). A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma. Nature Cancer. 5(9). 1390–1408. 14 indexed citations

Forchhammer, Stephan, Laura Del Regno, Georg Lodde, et al.. (2023). The impact of the COVID‐19 pandemic on the diagnosis of cutaneous melanomas: A retrospective cohort study from five European skin cancer reference centres. Journal of the European Academy of Dermatology and Venereology. 37(5). 922–931. 8 indexed citations

Ferretti, Lorenza P., Deena M. Leslie Pedrioli, Phil F. Cheng, et al.. (2023). Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma. Cancer Research. 83(23). 3974–3988. 11 indexed citations

Cheng, Phil F., et al.. (2023). Health‐related quality of life in survivors of advanced melanoma treated with anti‐PD1‐based immune checkpoint inhibitors. Cancer Medicine. 12(11). 12861–12873. 5 indexed citations

Purwin, Timothy J., Claudia Capparelli, Phil F. Cheng, et al.. (2023). Abstract 1301: Evolution of heterogenous BRAFi/MEKi+CDK4/6i resistance mechanisms and targeting site-specific resistant populations in metastatic cutaneous melanoma. Cancer Research. 83(7_Supplement). 1301–1301. 1 indexed citations

Kraehenbuehl, Lukas, Stephanie Schneider, Joanna Mangana, et al.. (2023). Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis. Pharmaceuticals. 16(7). 935–935.

Opitz, Lennart, et al.. (2022). Defining the Molecular Landscape of Cancer-Associated Stroma in Cutaneous Squamous Cell Carcinoma. Journal of Investigative Dermatology. 142(12). 3304–3312.e5. 5 indexed citations

10.

Dimitriou, Florentia, J.C. Hassel, Marlana Orloff, et al.. (2022). 832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM). Annals of Oncology. 33. S929–S929. 3 indexed citations

11.

Dimitriou, Florentia, Melike Ak, Ken Kudura, et al.. (2021). Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis. Cancers. 13(12). 2931–2931. 21 indexed citations

12.

Tastanova, Aizhan, Phil F. Cheng, Elisa Bellini, et al.. (2021). A Comparative Study of Real-Time RT-PCR–Based SARS-CoV-2 Detection Methods and Its Application to Human-Derived and Surface Swabbed Material. Journal of Molecular Diagnostics. 23(7). 796–804. 24 indexed citations

13.

Kempf, Werner, Joanna Mangana, Phil F. Cheng, et al.. (2020). The role of cyclin D1 and Ki‐67 in the development and prognostication of thin melanoma. Histopathology. 77(3). 460–470. 16 indexed citations

14.

Teh, Jessica L.F., Dan A. Erkes, Phil F. Cheng, et al.. (2020). Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors. Cancer Immunology Research. 8(9). 1114–1121. 13 indexed citations

15.

Cheng, Phil F., et al.. (2019). Inhibition of p38/MK2 Signaling Prevents Vascular Invasion of Melanoma. Journal of Investigative Dermatology. 140(4). 878–890.e5. 11 indexed citations

16.

Teh, Jessica L.F., Phil F. Cheng, Timothy J. Purwin, et al.. (2018). In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms. Cancer Discovery. 8(5). 568–581. 61 indexed citations

17.

Mellett, Mark, Barbara Meier, Deepa Mohanan, et al.. (2018). CARD14 Gain-of-Function Mutation Alone Is Sufficient to Drive IL-23/IL-17–Mediated Psoriasiform Skin Inflammation In Vivo. Journal of Investigative Dermatology. 138(9). 2010–2023. 69 indexed citations

18.

Hogan, Sabrina A., Anaïs Courtier, Phil F. Cheng, et al.. (2018). Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma. Cancer Immunology Research. 7(1). 77–85. 100 indexed citations

19.

Siliņa, Karīna, Alex Soltermann, Farkhondeh Movahedian Attar, et al.. (2017). Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. Cancer Research. 78(5). 1308–1320. 297 indexed citations

20.

Freiberger, Sandra N., Phil F. Cheng, Piotr Dziunycz, et al.. (2015). Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2. Molecular Cancer Therapeutics. 14(9). 2132–2142. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact